Key Laboratory of Targeted Intervention of Cardiovascular Disease and Collaborative Innovation Center for Cardiovascular Translational Medicine, Department of Pathophysiology, Nanjing Medical University, Nanjing, China.
Department of Anatomy and Histology, Nanjing Medical University, Nanjing, China.
Biochim Biophys Acta Mol Basis Dis. 2018 Oct;1864(10):3109-3121. doi: 10.1016/j.bbadis.2018.05.026. Epub 2018 Jun 14.
A host of pathogenic factors induce acute kidney injury (AKI) leading to insufficiencies of renal function. In the present study we evaluated the role of myocardin-related transcription factor A (MRTF-A) in the pathogenesis of AKI. We report that systemic deletion of MRTF-A or inhibition of MRTF-A activity with CCG-1423 significantly attenuated AKI in mice induced by either ischemia-reperfusion or LPS injection. Of note, MRTF-A deficiency or suppression resulted in diminished renal ROS production in AKI models with down-regulation of NAPDH oxdiase 1 (NOX1) and NOX4 expression. In cultured macrophages, MRTF-A promoted NOX1 transcription in response to either hypoxia-reoxygenation or LPS treatment. Interestingly, macrophage-specific MRTF-A deletion ameliorated AKI in mice. Mechanistic analyses revealed that MRTF-A played a role in regulating histone H4K16 acetylation surrounding the NOX gene promoters by interacting with the acetyltransferase MYST1. MYST1 depletion repressed NOX transcription in macrophages. Finally, administration of a MYST1 inhibitor MG149 alleviated AKI in mice. Therefore, we data illustrate a novel epigenetic pathway that controls ROS production in macrophages contributing to AKI. Targeting the MRTF-A-MYST1-NOX axis may yield novel therapeutic strategies to combat AKI.
许多致病因素可导致急性肾损伤 (AKI),从而导致肾功能不全。在本研究中,我们评估了肌球蛋白相关转录因子 A (MRTF-A) 在 AKI 发病机制中的作用。我们报告称,MRTF-A 的系统缺失或用 CCG-1423 抑制 MRTF-A 活性,可显著减轻由缺血再灌注或 LPS 注射引起的 AKI 小鼠模型的损伤。值得注意的是,在 AKI 模型中,MRTF-A 缺乏或抑制可导致肾 ROS 产生减少,其机制与 NADPH 氧化酶 1 (NOX1) 和 NOX4 表达下调有关。在培养的巨噬细胞中,MRTF-A 可促进缺氧再复氧或 LPS 处理后 NOX1 的转录。有趣的是,巨噬细胞特异性 MRTF-A 缺失可改善 AKI 小鼠模型的损伤。机制分析表明,MRTF-A 通过与乙酰转移酶 MYST1 相互作用,在调节围绕 NOX 基因启动子的组蛋白 H4K16 乙酰化方面发挥作用。MYST1 缺失可抑制巨噬细胞中的 NOX 转录。最后,MYST1 抑制剂 MG149 的给药可减轻 AKI 小鼠模型的损伤。因此,我们的数据说明了一种新的表观遗传途径,该途径可控制巨噬细胞中 ROS 的产生,从而导致 AKI。靶向 MRTF-A-MYST1-NOX 轴可能为治疗 AKI 提供新的治疗策略。